日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma

CDK4/6 和 PD-1 序贯抑制后肿瘤和免疫动力学:一项去分化脂肪肉瘤 II 期研究的结果

Rosenbaum, Evan; Gularte-Mérida, Rodrigo; Seffar, Evan; Lee, Jasme; Adamow, Mathew; Bradic, Martina; Dickson, Mark A; Avutu, Viswatej; Banks, Lauren B; Chan, Jason E; Chi, Ping; Gounder, Mrinal M; Kelly, Ciara M; Keohan, Mary Louise; Maki, Robert G; Movva, Sujana; Reed, Damon R; Desir, Rhoena; Biniakewitz, Matthew; Erinjeri, Joseph P; Lefkowitz, Robert A; Wong, Phillip; Antonescu, Cristina R; Qin, Li-Xuan; Panageas, Katherine S; Shen, Ronglai; Singer, Samuel; Koff, Andrew; Tap, William D; D'Angelo, Sandra P

A phase I study of the CSF1R inhibitor vimseltinib in combination with the PD-L1 inhibitor avelumab in patients with advanced sarcoma

一项针对晚期肉瘤患者的 I 期研究,评估 CSF1R 抑制剂 vimseltinib 与 PD-L1 抑制剂 avelumab 联合用药的疗效。

E Rosenbaum ,K Seier ,M Bradic ,S Movva ,C M Kelly ,M A Dickson ,M L Keohan ,M M Gounder ,P Chi ,B A Nacev ,J E Chan ,V Avutu ,M Biniakewitz ,S Jasnani ,M Duchemin ,R Desir ,P Wong ,J Erinjeri ,S Hwang ,C R Antonescu ,L-X Qin ,W D Tap ,S P D'Angelo

Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial

局部晚期或转移性肉瘤患者接受Talimogene Laherparepvec联合Pembrolizumab治疗的客观缓解率:一项II期临床试验

Kelly, Ciara M; Antonescu, Cristina R; Bowler, Timothy; Munhoz, Rodrigo; Chi, Ping; Dickson, Mark A; Gounder, Mrinal M; Keohan, Mary Louise; Movva, Sujana; Dholakia, Reena; Ahmad, Hamza; Biniakewitz, Matthew; Condy, Mercedes; Phelan, Haley; Callahan, Margaret; Wong, Phillip; Singer, Sam; Ariyan, Charlotte; Bartlett, Edmund K; Crago, Aimee; Yoon, Sam; Hwang, Sinchun; Erinjeri, Joseph P; Qin, Li-Xuan; Tap, William D; D'Angelo, Sandra P